Inovio Pharma (INO) Tops Q4 EPS by 13c

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.10), $0.13 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $103 million versus the consensus estimate of $217.65 thousand.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c